Silymarin use and liver disease progression in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis trial.
about
Silymarin for HCV infectionPrevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challengesLiver fibrosis and protection mechanisms action of medicinal plants targeting apoptosis of hepatocytes and hepatic stellate cellsSilymarin reduces profibrogenic cytokines and reverses hepatic fibrosis in chronic murine schistosomiasis.Processes to manage analyses and publications in a phase III multicenter randomized clinical trialReview article: prescribing medications in patients with cirrhosis - a practical guide.Complementary and alternative medications in hepatitis C infection.Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C.Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma.A randomized, multi-central, controlled study of patients with hepatitis B e antigen-positive chronic hepatitis B treated by adefovir dipivoxil or adefovir dipivoxil plus bicyclol.Failure of Intravenous Silibinin Monotherapy to Prevent Hepatitis C Genotype 2A Liver Graft ReinfectionHepatoprotective and antiviral functions of silymarin components in hepatitis C virus infection.Interaction of silymarin flavonolignans with organic anion-transporting polypeptides.Impact of oral silymarin on virus- and non-virus-specific T-cell responses in chronic hepatitis C infectionEffect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trialProtective mechanisms of medicinal plants targeting hepatic stellate cell activation and extracellular matrix deposition in liver fibrosis.Current drugs in early development for treating hepatitis C virus-related hepatic fibrosis.Chemoprevention against hepatocellular carcinoma.Effect of silymarin on biochemical indicators in patients with liver disease: Systematic review with meta-analysisSilybin-vitamin E-phospholipids complex reduces liver fibrosis in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin.Effects and tolerance of silymarin (milk thistle) in chronic hepatitis C virus infection patients: a meta-analysis of randomized controlled trials.Null anticarcinogenic effect of silymarin on diethylnitrosamine-induced hepatocarcinogenesis in ratsAntioxidant and hepatoprotective effects of silymarin phytosomes compared to milk thistle extract in CCl4 induced hepatotoxicity in rats.Natural History of Hepatitis C.Hepatoprotective effects of Cynara extract and silymarin on carbon tetrachloride-induced hepatic damage in rats
P2860
Q26851453-3B8EFE27-7184-478E-B5FB-3CE5CC8B7A4FQ28272678-2E9C383B-12CC-4546-8009-0D6C66E54C2DQ30369750-77A91EB2-D6A7-4091-A100-3B9CF253B1A6Q33622760-65778E5F-9350-4F29-B417-4810324AAFC8Q33694159-86082B6B-4C63-40AB-9B9F-8F7BD1491764Q34342554-C7361F36-625D-43DA-B237-B9C08C674B51Q34411345-92B5039F-A28B-4A07-B6E8-4EB1610726BFQ35579547-8EDC9AA0-A217-4511-91FE-0D68FB37CB91Q35619104-08794923-5172-4272-8F11-383FE6172C88Q35859123-98935003-5532-4F57-BF73-6B6480D2401DQ36142772-C1A4EF3B-8253-457E-B1EA-B69E7C80DE29Q36675737-3E38F7FB-5347-44C2-87C6-3DA212137059Q36776621-C04DE677-7AB0-4315-9883-8830BAFC8BD8Q36910728-32230FA2-251C-4D8E-BE5A-DDD0332CE0CEQ36933129-89DD265D-41F0-4591-9C16-34FA3B74D71AQ38326327-1D722BE7-5654-4878-A278-0CEEF3B4335EQ38540088-39056F3A-2F47-46F6-B855-DE464593E118Q38550165-EF4CE15D-B8A7-41EC-9B92-27AC252CD04DQ41122488-1F6070B1-DBE0-42AD-857B-64416AB1D44DQ41426862-3BB41F74-DC8A-4EA9-82B5-36765C1156CDQ41729153-55026D57-6686-4A5A-9EF4-6FC2501D9A66Q41918847-A00D9CAC-1CEB-4318-8556-0D1984F46901Q46228796-97F8A310-0E50-4811-B497-2A2A607F673EQ50934392-ECF953BD-4906-42A9-BE14-D97688E210B1Q57729865-5B296B57-F184-4786-90B5-4050A5EF3744
P2860
Silymarin use and liver disease progression in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis trial.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Silymarin use and liver diseas ...... tment against Cirrhosis trial.
@ast
Silymarin use and liver diseas ...... tment against Cirrhosis trial.
@en
type
label
Silymarin use and liver diseas ...... tment against Cirrhosis trial.
@ast
Silymarin use and liver diseas ...... tment against Cirrhosis trial.
@en
prefLabel
Silymarin use and liver diseas ...... tment against Cirrhosis trial.
@ast
Silymarin use and liver diseas ...... tment against Cirrhosis trial.
@en
P2093
P2860
P1476
Silymarin use and liver diseas ...... tment against Cirrhosis trial.
@en
P2093
C Morishima
E C Wright
HALT-C Trial Group
J E Everhart
N D Freedman
Z D Goodman
P2860
P304
P356
10.1111/J.1365-2036.2010.04503.X
P407
P577
2010-11-02T00:00:00Z